Antonio Llombart-Cussac, Amparo Ruiz, Antonio Antón, Agustí Barnadas, Silvia Antolín, José E. Alés-Martínez, Isabel Álvarez, Raquel Andrés, José A. García Saenz, Juan Lao, Eva Carrasco, Carmen Cámara, Isabel Casas and Miguel Martín Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer Cancer 118
Version of Record online: 29 JUN 2011 | DOI: 10.1002/cncr.26299
The authors designed an exploratory, open-label, randomized phase 2 study to investigate the activity and tolerability of exemestane and anastrozole as first-line hormone therapy and to explore the optimal aromatase inhibitor sequence in postmenopausal women with hormone-responsive, advanced breast cancer. A sequential strategy of anastrozole followed by exemestane appeared to be the more appropriate endocrine therapy option for these patients.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field